

nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 13, 1999.

A. Federal Reserve Bank of Boston (Richard Walker, Community Affairs Officer) 600 Atlantic Avenue, Boston, Massachusetts 02106-2204:

1. *Westborough Bancorp, M.H.C., and Westborough Financial Services, Inc.*, both of Westborough, Massachusetts; to become bank holding companies by acquiring 100 percent of the voting shares of Westborough Savings Bank, Westborough, Massachusetts.

Board of Governors of the Federal Reserve System, July 14, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99-18400 Filed 7-19-99; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225), to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 3, 1999.

A. Federal Reserve Bank of Chicago (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. *Firststar Corporation*, Milwaukee, Wisconsin (Firststar); to acquire all the nonbank subsidiaries of Mercantile Bancorporation, Inc., St. Louis, Missouri (Mercantile), and to engage, directly or indirectly through such nonbank subsidiaries, in a variety of nonbanking activities that have previously been determined to be permissible for bank holding companies. The nonbanking companies that Firststar proposes to acquire are listed in the notice filed with the Board, and include FFG Trust, Inc., Springfield, Illinois, Mercantile Trust Company National Association, St. Louis, Missouri, D.D. Development of Sterling, Sterling, Illinois, Mercantile Consumer Loan Company, Rock Island, Illinois, and Mississippi Valley Life Insurance Company, St. Louis, Missouri. The nonbanking activities of the companies to be acquired also are listed in the notice and include engaging in trust company functions, pursuant to § 225.28(b)(5) of Regulation Y; community development financing and investment activities, pursuant to § 225.28(b)(12)(i) of Regulation Y; making and servicing loans, pursuant to § 225.28(b)(1) of Regulation Y; and credit insurance activities, pursuant to § 225.28(b)(11)(i) of Regulation Y; and in engaging all activities that Mercantile currently is authorized to conduct.

Board of Governors of the Federal Reserve System, July 14, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99-18399 Filed 7-19-99; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and

recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on July 29, 1999, 8 a.m. to 5 p.m.

Location: Corporate Bldg., conference room 020B, 9200 Corporate Blvd., Rockville, MD.

Contact Person: Mary J. Cornelius, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2194, ext. 118, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12523. Please call the information Line for up-to-date information on this meeting.

Agenda: The committee will discuss, make recommendations, and vote on a premarket approval application for a urethral bulking and coaptation device for the treatment of stress urinary incontinence due to intrinsic sphincter insufficiency. The committee will also discuss possible revisions to the document entitled "Draft Guidance For Preparation of PMA Applications for Testicular Prostheses," issued March 16, 1993. Single copies of the draft guidance are available to the public by calling 1-800-899-0381 or 301-827-0111, and requesting Facts-On-Demand document number 809, or on the Internet at "<http://www.fda.gov/cdrh/ode/oderp809.html>".

Procedure: On July 29, 1999, from 8:30 a.m. to 5 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 23, 1999. Oral presentations from the public will be scheduled between approximately 9 a.m. and 9:30 a.m., and between approximately 3 p.m. and 3:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 23, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On July 29, 1999, from 8 a.m. to 8:30 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential commercial information (5 U.S.C. 552b(c)(4)) regarding present and future FDA issues.

FDA regrets that it was unable to publish this notice 15 days prior to the